|
|
|
|
| LEADER |
02795nam a22005295i 4500 |
| 001 |
14237 |
| 003 |
DE-He213 |
| 005 |
20130727075951.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130518s2013 gw | s |||| 0|eng d |
| 020 |
# |
# |
|a 9783319003030
|9 978-3-319-00303-0
|
| 024 |
7 |
# |
|a 10.1007/978-3-319-00303-0
|2 doi
|
| 050 |
# |
4 |
|a QR1-502
|
| 072 |
# |
7 |
|a PSG
|2 bicssc
|
| 072 |
# |
7 |
|a SCI045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 579
|2 23
|
| 100 |
1 |
# |
|a Byers, B. Rowe.
|e editor.
|
| 245 |
1 |
0 |
|a Iron Acquisition by the Genus Mycobacterium
|b History, Mechanisms, Role of Siderocalin, Anti-Tuberculosis Drug Development /
|c edited by B. Rowe Byers.
|h [electronic resource] :
|
| 264 |
# |
1 |
|a Heidelberg :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2013.
|
| 300 |
# |
# |
|a V, 92 p. 39 illus., 9 illus. in color.
|b online resource.
|
| 336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
| 337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
| 338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
# |
# |
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
# |
|a SpringerBriefs in Molecular Science,
|x 2191-5407
|
| 505 |
0 |
# |
|a A History of Iron Metabolism in the Mycobacteria -- Mycobacterial Iron Uptake Mechanisms -- Siderocalin Combats Mycobacterial Infections -- Design of Anti-TB Drugs Using the Iron Uptake Platform.
|
| 520 |
# |
# |
|a Iron Acquisition by the Genus Mycobacterium summarizes the early evidence for the necessity of iron in mycobacteria and the discovery of the mycobacterial siderophores mycobactin, carboxymycobactin, and exochelin. The structural characterization of the mycobacterial siderophores is described. �The genes so far identified as essential for iron acquisition and maintenance of an infection by pathogenic mycobacteria are discussed.� The potential role of siderocalin in iron gathering by M. tuberculosis is featured. Because new drugs for M. tuberculosis are needed, this brief also emphasizes the design of antibiotics that interfere with siderophore biosynthesis and the use of siderophore analogs and/or conjugates.
|
| 650 |
# |
0 |
|a Life sciences.
|
| 650 |
# |
0 |
|a Chemistry, inorganic.
|
| 650 |
# |
0 |
|a Bioorganic chemistry.
|
| 650 |
# |
0 |
|a Emerging infectious diseases.
|
| 650 |
# |
0 |
|a RNA-ligand interactions.
|
| 650 |
# |
0 |
|a Microbiology.
|
| 650 |
1 |
4 |
|a Life Sciences.
|
| 650 |
2 |
4 |
|a Microbiology.
|
| 650 |
2 |
4 |
|a Protein-Ligand Interactions.
|
| 650 |
2 |
4 |
|a Inorganic Chemistry.
|
| 650 |
2 |
4 |
|a Bioorganic Chemistry.
|
| 650 |
2 |
4 |
|a Infectious Diseases.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319003023
|
| 830 |
# |
0 |
|a SpringerBriefs in Molecular Science,
|x 2191-5407
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-3-319-00303-0
|
| 912 |
# |
# |
|a ZDB-2-SBL
|
| 950 |
# |
# |
|a Biomedical and Life Sciences (Springer-11642)
|